566 related articles for article (PubMed ID: 27354792)
1. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
[TBL] [Abstract][Full Text] [Related]
2. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
3. pH-sensitive nanoparticles for improved oral delivery of dapsone: risk assessment, design, optimization and characterization.
Chaves LL; Costa Lima SA; Vieira AC; Barreiros L; Segundo MA; Ferreira D; Sarmento B; Reis S
Nanomedicine (Lond); 2017 Aug; 12(16):1975-1990. PubMed ID: 28745104
[TBL] [Abstract][Full Text] [Related]
4. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Thirupathi G; Swetha E; Narendar D
Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
[TBL] [Abstract][Full Text] [Related]
5. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
[TBL] [Abstract][Full Text] [Related]
6. Characterization and stability of nanostructured lipid carriers as drug delivery system.
Abbasalipourkabir R; Salehzadeh A; Abdullah R
Pak J Biol Sci; 2012 Feb; 15(3):141-6. PubMed ID: 22866544
[TBL] [Abstract][Full Text] [Related]
7. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
8. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
9. The design of naproxen solid lipid nanoparticles to target skin layers.
Akbari J; Saeedi M; Morteza-Semnani K; Rostamkalaei SS; Asadi M; Asare-Addo K; Nokhodchi A
Colloids Surf B Biointerfaces; 2016 Sep; 145():626-633. PubMed ID: 27288817
[TBL] [Abstract][Full Text] [Related]
10. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
11. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
12. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
13. Ion pairing with linoleic acid simultaneously enhances encapsulation efficiency and antibacterial activity of vancomycin in solid lipid nanoparticles.
Kalhapure RS; Mocktar C; Sikwal DR; Sonawane SJ; Kathiravan MK; Skelton A; Govender T
Colloids Surf B Biointerfaces; 2014 May; 117():303-11. PubMed ID: 24667076
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
15. Development of "all natural" layer-by-layer redispersible solid lipid nanoparticles by nano spray drying technology.
Wang T; Hu Q; Zhou M; Xia Y; Nieh MP; Luo Y
Eur J Pharm Biopharm; 2016 Oct; 107():273-85. PubMed ID: 27470922
[TBL] [Abstract][Full Text] [Related]
16. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Das S; Ng WK; Kanaujia P; Kim S; Tan RB
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
[TBL] [Abstract][Full Text] [Related]
17. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
18. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
19. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SAC; Ferreira D; Sarmento B; Reis S
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):653-663. PubMed ID: 29433346
[TBL] [Abstract][Full Text] [Related]
20. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
